정규장
로그인 회원가입
LH
LH
Labcorp Holdings Inc
7월 27일 2:44 PM ET (한국 7/28 03:44)
$296.77
+5.75 ▲ +1.98%

랩코프 홀딩스(LH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$24.3B
미드캡
P/E
26.3
적정 수준
배당수익률
0.99%
52주 위치
97%
저점 +21% · 고점 -1%
애널리스트
매수
D
Fundamental health
vs. Diagnostics & Research
수익성
Top 66%
성장
Top 77%
밸류에이션
Top 88%
재무 안정
Top 40%
💰 Is this stock pricier than usual right now?
Compared to this company's own recent 5년 (not other companies).
Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 26원. Over the past 5년, it usually traded around 25원. Roughly in line with its own history.
Pricy doesn't mean bad — it means expectations are already baked in.
Index S&P 500P/E 26.3EPS (ttm) 11.29Insider Own 0.4%Shs Outstand 82.3MPerf Week 4.73%
Market Cap 24.34BForward P/E 15.25EPS next Y 8.02%Insider Trans -7.45%Shs Float 81.7MPerf Month 11.91%
Enterprise Value 30.61BPEG 1.75EPS next Q 4.78Inst Own 98.61%Short Float 3.47%Perf Quarter 12.02%
Income 0.94BP/S 1.72EPS this Y 9.61%Inst Trans -1.22%Short Ratio 4.17Perf Half Y 9.93%
Sales 14.14BP/B 2.8EPS next 5Y 8.73%ROA 5.13%Short Interest 2.83MPerf YTD 18.29%
Book/sh 106.06P/C 24.8EPS past 3/5Y -9.18% -8.01%ROE 11.05%52W High -0.56% ($298.45)Perf Year 10.86%
Cash/sh 11.96P/FCF 17.58Sales past 3/5Y 5.55% -0.04%ROIC 6.16%52W Low 21.37% ($244.52)Perf 3Y 35.62%
Dividend Est. $2.95 (0.99%)EV/EBITDA 13.55EPS Y/Y TTM 30.39%Gross Margin 26.81%Volatility(W/M) 2.76% 2.71%Perf 5Y 21.74%
Dividend TTM 2.88EV/Sales 2.16Sales Y/Y TTM 7.34%Oper. Margin 11.11%ATR (14) 7.8Perf 10Y 148.85%
Dividend Ex-Date 2026/8/28Quick Ratio 1.54EPS Q/Q 32.75%Profit Margin 6.66%RSI (14) 71.17Recom 1.59
Dividend Gr. 3/5Y 10.06% -Current Ratio 1.73Sales Q/Q 5.75%SMA20 5.57% ($281.11)Beta 0.87Target Price $313.56
Payout 27.54%Debt/Eq 0.83Earnings 2026/7/30SMA50 10.53% ($268.5)Rel Volume 1.34Prev Close $291.02
Employees 71000LT Debt/Eq 0.75EPS/Sales Surpr. 3.42% 0.82%SMA200 10.95% ($267.48)Avg Volume(3M) 0.68MPrice $296.77
IPO 1988/7/7Option/Short Yes/YesTrades 15831Volume 907,447Change 1.98%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $3.5B (YoY +6%) · 순이익 $278M (YoY +31%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Labcorp Holdings Inc (LH) Investment Analysis

What kind of company is Labcorp Holdings Inc?

랩코프 홀딩스(LH) 방어주
Healthcare · Diagnostics & Research
#536 by Market Cap — Mid-Cap

🔬 Labcorp Holdings (LH) is a global leading healthcare diagnostics company that provides comprehensive life sciences solutions worldwide, spanning from routine health diagnostics for individual patients to complex clinical trial support for pharmaceutical companies and next-generation drug development.

Learn more about Labcorp Holdings Inc →
Market Cap
$24.3B
Approx. KRW 33.3 trillion
⚖️ 8% of Samsung Electronics
Market Cap Rank536
Employees71,000people
IPO1988/07/07
Current Price$296.77 ≈ 406,575원
📌 S&P 500 · NYSE · USA

Key Events

⏰ Upcoming events
🔔 Earnings release D-3
예상 EPS $4.78
🎯 Ex-dividend date D-32
지급 9월 11일 (금)
💡 배당을 받으려면 8월 27일까지 매수하는게 좋습니다
📜 Recent events
🎯 Ex-div 2026년 5월 29일 (금) 주당 $0.72
🔔 Earnings release 2026년 4월 30일 (목) · 장 시작 전 EPS +3.4% 매출 +0.8%

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
11.1%
✓ 부진
My positionBottom 25%
Low range Average High range
Diagnostics & Research 대형주 Median 18.9% · Bottom 24%
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
6.7%
✓ 부진
My positionBottom 25%
Low range Average High range
Diagnostics & Research 대형주 Median 11.9% · Bottom 24%
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
26.8%
✓ 부진
My positionBottom 25%
Low range Average High range
Diagnostics & Research 대형주 Median 50.2% · Bottom 13%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
11.1%
✓ 평균
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 11.9% · Bottom 47%
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
5.1%
✓ 양호
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 5.1% · Around average
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
6.2%
✓ 평균
My positionMid-range
Low range Average High range
Healthcare 대형주 Median 7.4% · Bottom 44%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.83
✓ Average
My positionMid-range
Low range Average High range
Diagnostics & Research Median 0.38
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
1.73
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 2.23
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.54
✓ 양호
My positionMid-range
Low range Average High range
Diagnostics & Research Median 2.15
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$313.56
현재가 대비 +5.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
15.25배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
1.75
다소 비쌈
💡 PEG 1.5~2 — 성장 대비 다소 비쌈
내년 EPS 예상 성장률
+8.0%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+8.7%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Reliability
Beat estimates in 1 of the last 1 quarters
1
예상 상회
0
예상 부합
0
예상 하회
100%
상회 비율
+3.3%
평균 서프라이즈
2026.04.30
상회
실적 $4.25 · 예상 $4.12 +3.3%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+9.6%
양호
My positionMid-range
Low range Average High range
방어주 대형주 Median 9.6% · Top 50%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+8.0%
부진
My positionBottom 25%
Low range Average High range
방어주 대형주 Median 10.8% · Bottom 18%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+8.7%
평균
My positionMid-range
Low range Average High range
방어주 대형주 Median 9.8% · Bottom 25%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-9.2%
부진
My positionBottom 25%
Low range Average High range
방어주 대형주 Median 4.7% · Bottom 21%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-8.0%
부진
My positionBottom 25%
Low range Average High range
방어주 대형주 Median 4.1% · Bottom 11%
Past 5-Year Revenue
How much revenue grew over the past 5 years
-0.0%
매우 부진
My positionBottom 5%
Low range Average High range
방어주 대형주 Median 6.7% · Bottom tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+5.8%
평균
My positionMid-range
Low range Average High range
방어주 대형주 Median 8.4% · Bottom 38%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -46%p below the market
LH +21.7% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-46.2%p
Significantly behind the market
vs Health Care (XLV)
-1.9%p
roughly in line with the sector average
1-year basis
vs S&P 500
-5.6%p
slightly behind the market
vs Health Care (XLV)
-8.9%p
slightly behind the sector average
Rank among peers
5-year return Upper-Mid (26%) Based on 15 peers
1-year return Lower-Mid (lower 40%) Based on 15 peers
Current position within 52-week range
Low (-21.4%p) High (-0.6%p)
Current price is 21.4% above the 52-week low and 0.6% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-13.6%
Annualized volatility
23.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

⚠️
Current diagnosis · 2026-07-24
Overbought zone — short-term pullback possible

Current price $296.77 broke above the upper band ($292.80). Stronger buying than average, but signals short-term overheating. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-24
Bullish momentum holding

MACD 5.418 > Signal 4.398 in positive zone + Hist positive (+1.020). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️
Current diagnosis · 2026-07-24
Overbought zone — short-term pullback possible

RSI 71.2 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 95.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Assets·Vs. Sales·Vs. Cash Flow
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
26.30x
✓ Very cheap
My positionTop 25%
Low range Average High range
Diagnostics & Research median 35.22x · Top 22% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
15.25x
✓ Very cheap
My positionTop 5%
Low range Average High range
Diagnostics & Research median 22.77x · Top 1% — relatively cheap within the industry
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
2.80x
✓ Cheap
My positionMid-range
Low range Average High range
Diagnostics & Research median 3.37x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
1.72x
✓ Very cheap
My positionTop 5%
Low range Average High range
Diagnostics & Research 대형주 median 5.41x · Top 1% — relatively cheap within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
13.55x
✓ Very cheap
My positionTop 25%
Low range Average High range
Diagnostics & Research median 22.23x · Top 13% — relatively cheap within the industry
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
17.58x
✓ Very cheap
My positionTop 5%
Low range Average High range
Diagnostics & Research median 29.34x · Top 1% — relatively cheap within the industry
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$313.56 vs. current price +5.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Diagnostics & Research

Who owns it?

Ownership flow shows some pressure
Insider modest net selling -7.5% · Institutional net selling -1.2% · Short interest light 3.5%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-7.5%
Insiders net selling
🏦 Institutions (funds & investors)
-1.2%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 98.6%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 0.4%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 1.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
3.5%
Low — limited short-side pressure
Healthcare 대형주 Median 3.6%
Past 90 days Little change
Short interest days to cover
4.2 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 82.3M주
Float (tradable shares) 81.7M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding LH

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 0.99%
배당보다 주가 성장에 가까운 비중
Dividend Yield
0.99%
Industry average 1.25%
Dividend Per Share
$2.95
Annualized
Payout Ratio
28%
Share of net income paid as dividends
5-Year Growth
-
Annualized dividend growth
📅 지급월 2월 · 8월 · 11월
📊 총 이력 1990~2026 (30건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.13
1990
$0.43 +233.3%
1991
$0.82 +90.0%
1992
$0.69 -15.8%
1993
$0.17 -75.0%
1994
$1.86 +980.0%
2022
$2.68 +44.3%
2023
$2.88 +7.6%
2024
$2.88 +0.0%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 30건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-02-27
$0.720
1.25%
2025-11-26
$0.720
1.34%
2025-08-28
$0.720
1.31%
2025-05-29
$0.720
1.17%
2025-02-27
$0.720
1.16%
2024-11-26
$0.720
1.21%
2024-08-29
$0.720
1.25%
2024-05-24
$0.720
1.44%
2024-02-26
$0.720
1.29%
2023-11-07
$0.720
1.59%
2023-08-07
$0.720
1.49%
2023-05-17
$0.619
1.66%
2023-02-22
$0.619
1.19%
2022-11-16
$0.619
0.89%
2022-08-17
$0.619
0.57%
2022-05-18
$0.619
0.30%
1994-03-29
$0.172
2.96%
1993-12-29
$0.172
2.88%
1993-09-29
$0.172
2.06%
1993-06-29
$0.172
1.78%
1993-03-31
$0.172
2.28%
1992-12-29
$0.172
2.16%
1992-09-28
$0.172
1.86%
1992-06-26
$0.172
1.83%
1992-03-31
$0.150
1.37%
1992-01-06
$0.150
0.99%
1991-09-30
$0.150
1.22%
1991-06-27
$0.150
0.99%
1991-04-04
$0.129
0.63%
1990-12-31
$0.129
0.55%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 8,449원
5년 누적 (세후) 4.2만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
LH LH This Stock
$24.3B26.3 2.8 11.05% 0.99% +2.0%
LLY
$1.13T43.0 36.2 107.64% 0.58% +0.9%
JNJ
$634.1B30.5 7.5 25.74% 2.04% +1.6%
ABBV
$458.2B127.9 - 15221.82% 2.65% +0.9%
UNH
$382.1B27.1 3.9 12.49% 2.15% -0.7%
MRK
$323.7B36.9 7.1 18.97% 2.49% +0.5%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 랩코프 홀딩스(LH)?

랩코프 홀딩스(LH) belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is the market cap of LH?

The market cap of LH is approximately $24.3B, ranking 536 within its sector.

Does LH pay dividends?

LH has a dividend yield of approximately 0.99%, with an annual dividend of $2.95.

What is the P/E ratio of LH?

LH has a P/E ratio of approximately 26.3x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for LH?

LH has recorded a 52-week high of $298.45 and a low of $244.52.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.